Funded Startups in Montreuil
Recent disclosed rounds in Montreuil span from 2021-07-01 (MyC, $2M) to 2025-10-14 (Upciti, $20M), with the newest funding dated 2025-10-14 and the oldest…
Recent disclosed rounds in Montreuil span from 2021-07-01 (MyC, $2M) to 2025-10-14 (Upciti, $20M), with the newest funding dated 2025-10-14 and the oldest in 2021. The largest disclosed amount is Upciti’s $20M (Series A on 2025-10-14), which is substantially above the next-highest disclosed round of $12M (Spareka, Series B on 2023-03-07), creating a clear funding-size outlier within this slice.
The five entries also cluster around stage and sector choices: three of the five are in life sciences or health-adjacent categories (BforCure in Biotechnology at $9M on 2022-03-16; MyC in Health Care at $2M on 2021-07-01), while two are in commerce/financial services (Spareka $12M on 2023-03-07; Keewe $1M on 2022-05-05). Stage labeling is split as well: three rows have explicit named stages (Series A, Series B, Seed) while two use “Venture - Series Unknown” for BforCure ($9M, 2022-03-16) and MyC ($2M, 2021-07-01).
Most recent rounds
5 shownRelated listings
Frequently asked
Which disclosed round is the outlier in Montreuil, and how does it rank versus the others shown?
Upciti’s $20M Series A on 2025-10-14 stands out as the largest disclosed amount, well above Spareka’s $12M (2023-03-07) and the rest ($9M, $2M, and $1M). This makes the top disclosed round meaningfully larger than every other disclosed value in the five-row slice.
Do these Montreuil rounds cluster in time, or are they spread evenly across years?
They span roughly four years (2021-07-01 through 2025-10-14). Two rounds fall in 2022 (BforCure $9M on 2022-03-16 and Keewe $1M on 2022-05-05), while the only 2023 entry is Spareka’s $12M on 2023-03-07, and 2025 is represented solely by Upciti’s $20M on 2025-10-14.
How dominant are life-science/health categories versus other themes in this Montreuil set?
Three of the five companies are life-science/health-adjacent: BforCure (Biotechnology, $9M on 2022-03-16) and MyC (Health Care, $2M on 2021-07-01), with the remaining two in Data/Analytics (Upciti, $20M on 2025-10-14), Commerce/Shopping (Spareka, $12M on 2023-03-07), and Financial Services (Keewe, $1M on 2022-05-05).
What does the stage mix look like when stages are explicitly labeled versus “Series Unknown”?
Named stages appear on three entries: Upciti (Series A, $20M on 2025-10-14), Spareka (Series B, $12M on 2023-03-07), and Keewe (Seed, $1M on 2022-05-05). Two entries are labeled “Venture - Series Unknown” (BforCure $9M on 2022-03-16 and MyC $2M on 2021-07-01), so that labeling is a material share of the slice.
Which entries are at the low end of disclosed funding, and do they also align with a particular stage or sector?
The smallest disclosed amount is Keewe’s $1M Seed round on 2022-05-05 (Financial Services). The next-lowest disclosed amount is MyC’s $2M on 2021-07-01 (Health Care, labeled “Venture - Series Unknown”), so the lower end combines early-stage labeling and health/health-adjacent categorization.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.